Sodium‐glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve hepatic steatosis in patients with non‐alcoholic fatty liver disease (NAFLD) and type 2 diabetes, but data in patients without diabetes are lacking. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.